Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Poncelet

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Human Vaccines|September 6, 2011
Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 yearsTino F Schwarz, Marek Spaczynski, Achim Schneider, et al.
Neuropharmacology|February 1, 1994
Neuropharmacological characterization of SR 140333, a non peptide antagonist of NK1 receptorsM Jung, R Calassi, J Maruani, et al.
Life Sciences|January 1, 1995
SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptorX Emonds-Alt, D Bichon, J P Ducoux, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 17, 2001
Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor functionR Steinberg, R Alonso, G Griebel, et al.
Human Vaccines|October 25, 2008
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccineFrancis J Dessy, Sandra L Giannini, Catherine A Bougelet, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1997
Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonistD Gully, B Labeeuw, R Boigegrain, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 24, 1999
SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterizationE Bignon, R Alonso, M Arnone, et al.
Neuropeptides|December 31, 1997
Biochemical and pharmacological activities of SR 144190, a new potent non-peptide tachykinin NK2 receptor antagonistX Emonds-Alt, C Advenier, C Cognon, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Human Vaccines|September 6, 2011
Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 yearsTino F Schwarz, Marek Spaczynski, Achim Schneider, et al.
Neuropharmacology|February 1, 1994
Neuropharmacological characterization of SR 140333, a non peptide antagonist of NK1 receptorsM Jung, R Calassi, J Maruani, et al.
Life Sciences|January 1, 1995
SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptorX Emonds-Alt, D Bichon, J P Ducoux, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 17, 2001
Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor functionR Steinberg, R Alonso, G Griebel, et al.
Human Vaccines|October 25, 2008
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccineFrancis J Dessy, Sandra L Giannini, Catherine A Bougelet, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1997
Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonistD Gully, B Labeeuw, R Boigegrain, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 24, 1999
SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterizationE Bignon, R Alonso, M Arnone, et al.
Neuropeptides|December 31, 1997
Biochemical and pharmacological activities of SR 144190, a new potent non-peptide tachykinin NK2 receptor antagonistX Emonds-Alt, C Advenier, C Cognon, et al.
Pageof 6